Despite a promising approach for certain leukemia patients, the path to market appears to be in question.
| less than a minute read
This CD22 Approach Highlights the Importance of Experimental Medicine - and Collaboration
The therapy was developed at the National Cancer Institute, and Dr. Mackall said researchers did not know if a company would try to bring it to market.
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-11-19-15-40-01-479-6aff1851ff5130799d088a3b.png)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-11-06-17-39-37-187-6aee10d9e051d7ffd7756b19.jpeg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-29-16-59-13-899-6abbee61460fb9469a25b973.jpg)